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A VACCINE TO PREVENT MALARIA 
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Human Stages5 Mosquito Stage5 
Exo-erythrocytic stage Erythrocytic Stage Sexual Stage 
1) A Malaria-infected mosquito inoculates the sporozoites into a 
human host and they are transported through out the blood till 
the liver. 
2) Sporozoites infect liver cells. 
3) Formation of schizonts. 
4) Rupture of liver cell membranes and release of the merozoites. 
 
5) Merozoites infect erythrocytes and suffer multiples rounds of 
nuclear division without cytokinesis. 
6) Rupture of the erythrocyte. Merozoites are able to infect other 
erythrocytes. 
7) Merozoits can differentiate into sexual forms known as 
gametocytes (macrogametocytes and microgametocytes). 
8) Ingestion of gametocytes by the mosquito vector Anofeles. 
 
9) Mosquito vector induces gametogenesis: production of gametes. 
Microgametes fertilize macrogametes, leading a zygote. 
10)Zygote develops into a motile ookinete. 
11)The ookinete penetrates into the gut cells and it develops into an 
oocyst. 
12)Rupture of the oocyst and release of the sporozoites, which 
migrate to the salivary glands of the mosquito. 
RTS,S MSP3-LSP Pfs25-CP VLP 
Action 
Protection against the invasion of sporozoits. 
Inhibition of the development of the parasite in liver 
cells4. 
Prevent merozoit multiplication and invasion of erythrocytes8 
Prevent the transmission, gametocytes could not produce 
sporozoits8 
Target Plasmodium falciparum circumsporozoite protein (CSP)6 Surface protein of merozoit Plasmodium falciparum (MSP-3)8 Specie-specific gametocytes of Plasmodium falciparum (Pfs25)4 
Adyuvants AS01 and AS02, AS01 more immunogenic6,7 Alum and Montanide ISA7209 
Effects 
Antibodies anti-CSP IgG 
Lymphocytes T CD4+ and CD8+ proliferation  block the 
invasion into the liver cells 
IFN- production  macrophages activation  parasite 
decreases 4,6 
Trials: 
• Induction of B and T cell responses 
• IFN- and antibody secretion 
Similar effects to the natural immunity, except: 
• IgG1 > IgG3 
• Faster10 
Induction of an antibody serum which blocks the transmission11 
Response  Humoral > Cellular7 Humoral and cellular9 
Last Short term, keep IFN- levels7 12 months9 6 months (study time) 11 
Efficacy 
AS01  53% (5-17 months) 
AS02  31% (6-12 weeks) and 50% (5-10 months)4,7 
60% presented immunity 
70% of volunteers reacted to the vaccine 
Adjuvant Alum has an advantage9 
Adverse 
effects 
No4,7 Alum is more tolerable9 
Phase Phase III Phase I Previous studies of Phase I11 
Conclusion 
RTS,S/AS01 is an appropriate candidate, it allows 
continuing with Phase III of vaccination7 
The results encourage to continue with the studies Satisfactory results, in 2011 starts the Phase I11 
Laia Cuesta Casanovas 
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Malaria is a potentially mortal disease caused by four different species of the 
parasite Plasmodium, which are transmitted by the bite of Anofeles mosquitoes 
infected by the parasite1. According to the World Organization Of Health (WHO), 
mortality is about 1.1 million of people every year. Despite of it, between 2000 
and 2012, it was estimated that 3.3 million lives had been saved thanks to 
different treatments to control Malaria in Sub-Saharan Africa2,3. 
Vaccines which are well known nowadays allow a certain control of the illness, 
but not its eradication by the total elimination of the parasite4. 
OBJECTIVES 
This study revises the recent state of Malaria 
vaccine handled to control the disease in 
countries with a major incidence. With this 
information, it tries to infer which vaccine would 
be the appropriate one to prevent Malaria. 
CONCLUSIONS 
• RTS,S is the only candidate vaccine in Phase III of the studies. The results analysed in this review show 
that it could be a good vaccine for preventing Malaria. It shows 53% efficacy in children between 5 and 
7 months and it does not present adverse effects. 
• MSP3-LSP and Psf-CP VLP could also be considered good vaccines, despite they are on the first phases 
of the studies. 
• In Phase I of MSP3-LPS it was shown 77% efficacy, which encourages to continue the studies. 
• Studies based on Psf-CP VLP show an induction of antibodies with the total block of the 
transmission activity. Those results allow the beginning of Phase I. 
Plasmodium falciparum life cycle (modified image)1 
